Profit Matters! Small Stocks. Huge Gains.

Orchid Ventures, ORCD, ORVRF, Received a License to Distribute Cannabis in California

Written by Editor

Orchid Ventures Announces State Approval of a Type 11 Distribution License

CA Forrest Green Distribution, LLC, a subsidiary of Orchid Ventures, is granted a provisional distribution license by the BCC

IRVINE, CA / ACCESSWIRE / August 9, 2019 / Premium cannabis brand Orchid Ventures, Inc. (OTC PINK:ORVRF) (CNSX:ORCD) (“Orchid Ventures” or the “Company”) announces the Bureau of Cannabis Control (“BCC”) has granted the Company a provisional distribution license.

Orchid Venture, Inc.'s subsidiary, CA Forrest Green Distribution, LLC, a California limited liability company, was approved for a provisional Type 11 Cannabis distribution license with the Bureau of Cannabis Control (C11-0000967-LIC) for its Long Beach location. The Type 11 distribution license gives licensees the ability to distribute products, store, package, test, transport, re-package, label, and re-label cannabis, including pre-rolled cannabis for retail sale.

Orchid Ventures plans to use the licensed facility as a packaging and distribution center. Although this is a distribution license, the Company doesn’t plan to self distribute products in California.

“This furthers our California footprint and our ability to maintain appropriate stock levels and adds agility to our supply chain,” commented Orchid Ventures CEO and Director, Corey Mangold. “We have a great distributor in California in Indus Holdings, Inc. (CSE:INDS) and have no intention or interest in moving away from this partnership, in fact we are working with Indus to further our involvement and partnership.”

In addition, last week Orchid Ventures hired Rick Brown as its President. Orchid Ventures is paying Mr. Brown partially in stock the total of 200,000 shares of common stock (“Shares”) at CAD$.30 per share and is granting him an option to purchase 1,200,000 Shares at CAD$.30 pursuant to the Company’s 2019 Stock Option Plan. None of the Shares have been or will be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and any Shares are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the securities issued under an exemption from the registration requirements of the U.S. Securities Act will be “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and will contain the appropriate restrictive legend as required under the U.S. Securities Act.

ABOUT ORCHID ESSENTIALS

Orchid Essentials is an Irvine, Calif.-based brand that launched in Oregon and California in August 2017 and has since developed a mass-market brand and loyal consumer following with its premium vape products. Orchid’s products lines are currently sold in 350+ dispensaries across California and Oregon and are handcrafted and designed for maximum flavor and overall enjoyment. The company’s proven processes and passion for what it does carry through into its products. The end result is an unparalleled experience for new and practiced cannabis users alike. Orchid plans to expand its brand into new national markets, as well as global markets such as Latin America and Europe. With a continued focus on brand and intellectual property development, Orchid will execute strategic acquisitions to solidify an integrated cannabis manufacturing and distribution infrastructure with the goal of becoming a dominant premium cannabis brand in the United States. Orchid's management brings significant branding, product development and distribution experience with a proven track record of scaling revenues, building value generating partnerships and creating enterprise value. Learn more at https://orchidessentials.com/.

ON BEHALF OF THE BOARD OF DIRECTORS - ORCHID VENTURES, INC.

Corey Mangold
CEO and Director
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Investor Relations
Antonio Cruz
(949) 769-3859
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE

source: Orchid Ventures

Are Synthetic Cannabinoids safe? Synthetic Opioids, Fentanyl could kill instantly

E-mail

Written by Editor

Synthetic cannabinoids: What are they?

Synthetic cannabinoids can cause severe illness and death.

Warning! The Illinois Department of Public Health (IDPH) has received reports of multiple cases, including some deaths, of severe bleeding among people who have used contaminated synthetic cannabinoids. Other states also have reported similar cases. If you have purchased any of this product (e.g., K2, spice, and synthetic marijuana) since March 1, 2018, do not use it. In addition to these particular products, consumption of any synthetic marijuana poses health risks and should be avoided. If you have used any of these products and start experiencing severe, unexplained bleeding or bruising, please have someone take you to the hospital immediately or call 911. Do not walk or drive yourself. Tell your health care providers about the possible link between your symptoms and synthetic cannabinoid use. CDC’s Clinical Action alert

See how one small company trading on OTC went from a mere $0.20 cents to $9.00 in just 6 months!

CVSI has risen rapidly in the past six months, the company’s market cap is well over $700 million dollars today!

CVSI was known previously as CannaVest Corp. came under SEC scrutiny in the past. See the details below:

https://dailystockdeals.com/more/financial-press/1235-sec-charges-ceo-and-hemp-oil-company-with-fraud-securities-and-exchange-commission-v-cannavest-corp-a-k-a-cv-sciences-cvsi-and-michael-j-mona-jr

CVSI is now on a tear after reaching a settlement with the SEC.

A remarkable story of CVSI see chart

Synthetic cannabinoids are not one drug. Hundreds of different synthetic cannabinoid chemicals are manufactured and sold. New ones with unknown health risks become available each year. Synthetic cannabinoids are popular because users often believe they are legal and relatively safe.

These chemicals are called cannabinoids because they act on the same brain cell receptors as tetrahydrocannabinol (THC), the main active ingredient in marijuana. However, the hundreds of known synthetic cannabinoid chemicals and THC are different chemicals. In fact, synthetic cannabinoids may affect the brain in different and unpredictable ways compared to marijuana.

Synthetic cannabinoids are used in a variety of ways:

· Sprayed onto plant material and smoked

· Mixed into a liquid and vaped in electronic nicotine delivery devices (such as e-cigarettes)

· Added to herbal tea or to food and swallowed

Synthetic cannabinoids are widely available.

Consumers can buy synthetic cannabinoids in convenience stores, from individual drug dealers, or online as incense or natural herbal products.They are sold under a number of brand names, including

· K2

· Spice

· AK-47

· Mr. Happy

· Scooby Snax

· Kush

· Kronic

Many synthetic cannabinoids are illegal.

· The federal government has banned many specific synthetic cannabinoids. Many state and local governments have passed their own laws targeting other synthetic cannabinoids.

· Recent federal and state laws targeting synthetic cannabinoids have banned general categories of ingredients, rather than specific chemicals.

· Makers of synthetic cannabinoids try to get around these laws by creating new products with different ingredients or by labeling them “not for human consumption.”

Synthetic cannabinoid products are unsafe. It is hard to know what the products contain or what your reaction to them will be.

· There are no standards for making, packaging, or selling synthetic cannabinoid chemicals. That means that two packets of a brand-named product may have completely different chemicals.

· The amount of the synthetic cannabinoid chemical(s) can vary between batches or even within the same batch.

· Synthetic cannabinoid products may also be contaminated with other drugs or toxic chemicals, such as synthetic cathinones (“bath salts,” “flakka”).

Synthetic cannabinoids can harm your health.

Synthetic cannabinoids can cause severe illness and death.

Synthetic cannabinoids can affect brain function. Signs and symptoms include:

· Agitation and irritability

· Confusion and concentration problems

· Hallucinations, delusions, psychosis, suicidal thoughts, and violent behavior

· Seizures

· Sleepiness and dizziness

Fentanyl: a powerful synthetic opioid, is often mixed into heroin or cocaine. It is 50 times more powerful than heroin, 100 times more powerful than morphine and can kill a user almost instantly.

By Sari Horwitz

Reporter

Washington Post

CONCORD, N.H. — Attorney General Jeff Sessions on Thursday ordered federal prosecutors in 10 areas that have been especially hard-hit by overdose deaths from fentanyl to bring drug charges against anyone suspected of dealing the synthetic opioid, regardless of quantity.

An additional prosecutor will also be sent to each of the designated areas in Ohio, Tennessee, Kentucky, West Virginia, Maine, California and Pennsylvania as well as in New Hampshire, Sessions said.

“Fentanyl is a killer drug,” Sessions said in an interview Thursday morning as he flew to New Hampshire to meet with state and local law enforcement officials about the fentanyl crisis. “Fentanyl is so powerful that the slightest error in how much you take can go from this extremely pleasurable feeling to death.”

According to the Centers for Disease Control and Prevention, more than 42,000 Americans died of opioid overdoses in 2016, a figure driven by a dramatic surge in deaths from fentanyl and other synthetic opioids.

West Virginia had the highest number of drug overdoses, with 52 deaths per 100,000 residents, while New Hampshire and Ohio were the next-highest-ranking states, with 39 deaths per 100,000 residents.

“Having a prosecutor solely dedicated to working these fentanyl cases is going to be a huge, enormous benefit to us here,” said Brian Boyle, the Drug Enforcement Administration special agent in charge of the New England Field Division, who described the fentanyl problem as “scary.”

“The amount of fentanyl we’re seeing is affecting everybody, all walks of life, all communities,” Boyle said. “You’re seeing it in rural areas, urban areas, big cities, middle-of-nowhere areas in New England.”

Fentanyl, a powerful synthetic opioid, is often mixed into heroin or cocaine. It is 50 times more powerful than heroin, 100 times more powerful than morphine and can kill a user almost instantly.

Source: CDC, Washington Post, Oxbridge Research, Daily Stock Deals

Pump and Dump schemes on the World’s Biggest Crypto Exchanges.Crypto, ICO Scams are Bigger than you think.

E-mail

Written by Administrator
Monday, 13 August 2018 09:27
The Wall Street Journal carried out in-depth analysis of the biggest crypto currency exchanges and found that hundreds of currencies are being actively manipulated by dozens of pumpers. These Pump and Dump schemes generated over $825 million dollar in trading volume and $100s of millions of losses for traders who caught in the middle. The scammers are using Messaging Apps and Private Chat Rooms to pump and dump at will. The Wall Street Journal investigators found obscure ICOs with very little trading activity ‘prior to pump’ jump more than 70% in a matter of minutes. See the chart of Cloakcoin below. Cloakcoin trading activity on Binance.
Last Updated on Monday, 20 August 2018 23:03

Anthera Pharma, ANTH, Profile, Summary

E-mail

Written by Editor

Anthera Pharma, ANTH, Profile, Summary

Anthera Pharmaceuticals (ANTH) is a clinical-stage biopharmaceutical company focused on developing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and B-cell associated renal diseases.

The company was developing a Cystic Fibrosis drug called ‘Sollpura’ ,the drug was being developed in partnership with Eli Lilly, Sollpura was targeted for people who were suffering from Cystic Fibrosis which also affects pancreas and makes it much harder to digest food, the slow progression of indigestion could lead to adverse outcome including death.

Sollpura was a ‘pure’ PIG FREE drug, unlike other drugs on the market which are derived from Pig Enzymes, Sollpura was Kosher-Halal drug so people who prefer to avoid the consumption of drugs derived from Pigs were naturally very excited about this brand new drug.

The drug was in ‘third stage’ of clinical trials, unfortunately, the drug didn’t meet the expectation and wasn’t as effective in the late stage trials, so the company, after years of research and 100s of millions of expense, had no choice but to suspended all clinical trials of Sollpura.

The CEO released the following statement:

“We are greatly disappointed by the findings of the RESULT study,” shared Craig Thompson, President & CEO.

“We would like to extend our deepest gratitude to the patients and their families, study investigators, and the cystic fibrosis community for the support they have provided in the clinical development of Sollpura.”

As a result Anthera Pharmaceuticals was delisted from NASDAQ and currently trading on OTC Markets. The company has also been working on Kidney disease for a long time.

Blisibimod

Blisibimod was licensed from Amgen in December 2007 with exclusive worldwide rights. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy, systemic lupus erythematosus, or lupus, and others.

Blisibimod is currently in development for the treatment of IgA nephropathy (IgAN). IgAN (also known as Berger’s disease) is the most common cause of primary glomerulonephritis worldwide, occurring more frequently in Asia than in Europe or North America. IgAN is characterized by deposition of IgA-anti IgA immune complexes in the kidney, resulting in inflammation, the leakage of blood and protein into the urine, and loss of kidney function. The disease typically progresses slowly but as many as 40-50% of patients will eventually develop end-stage-renal disease and require dialysis or kidney transplant. There are currently no approved therapies for IgA nephropathy

Bright • SC

The Phase 2 BRIGHT-SC study enrolled 57 patients with biopsy-proven IgAN, 42 of whom completed at least 60 weeks of evaluation and 21 of whom completed at least 104 weeks. Two interim analyses showed favorable trends as compared to placebo on the progression of proteinuria and expected pharmacological effects (reductions in circulating B cells and serum immunoglobulins). Dosing is now completed and study results are expected in Q3 2017. Patients with persistent proteinuria (1-6 g/24hrs), despite stable background optimized therapy with angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) for at least 90 days and estimated glomerular filtration rate >30mL/min/1.73m², were randomized to receive either blisibimod (300mg/week for 8 weeks and 200mg/week thereafter) or matching placebo for up to 104 weeks and had the option of being followed thereafter in the absence of study drug to assess longer term outcome. ACEi or ARB was continued throughout the trial as background medication. Patients were not allowed to receive corticosteroids for the treatment of IgA nephropathy within 3 months of screening.

In the most recent interim analysis, the effects of blisibimod versus placebo were assessed through at least the 48 week time point in all patients. Patients had biopsy-proven IgA nephropathy with a mean proteinuria level of 2.4 grams and an estimated glomerular filtration rate of less than 70 mL/min/1.73m² – indicative of stage 2 chronic kidney disease per the National Kidney Foundation. A positive trend on proteinuria by blisibimod was observed. Consistent with the previously announced Week 24 analysis, blisibimod treated-patients over time demonstrated stable to slightly decreased levels of proteinuria, as assessed by urinary protein to creatinine ratio (PCR), as compared to slowly increasing levels of proteinuria in the placebo group. 44 of the original 57 patients had a Week 48 observation and 22 patients had a Week 96 observation at the time of this analysis.

Source: The Company, OTCking, Daily Stock Deals, OTC Stock Wire

If you want to get your company featured on OxBridge Research or want to learn more, please contact the editor. Thank you!

eXp World Holdings, EXPI, Corporate Profile

E-mail

Written by Administrator

eXp World Holdings, EXPI, Profile:

eXp World Holdings, Inc. is the holding company for a number of companies most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage® as a full-service real estate brokerage providing 24/7 access to collaborative tools, training, and socialization for real estate brokers and agents through its 3-D, fully-immersive, cloud office environment. eXp Realty, LLC and eXp Realty of Canada, Inc. also feature an aggressive revenue sharing program that pays agents a percentage of gross commission income earned by fellow real estate professionals who they attract into the Company. As a publicly-traded company, eXp World Holdings, offers professionals within its ranks opportunities to earn equity awards for production and contributions to overall company growth.

The home buying and selling process remains unfamiliar and often times emotional for most consumers. Consumers still depend on agents to help navigate the process, give insight into and lend a comparative perspective on properties, provide local market expertise, and negotiate and advocate on their behalf. Because of the magnitude of the buying or selling decision, the size of the asset that underlies that decision, and the emotional responses it frequently triggers, the vast majority of consumers will continue to rely upon agents and brokers for the foreseeable future.

With the emergence of the internet as the most powerful property marketing and advertising medium and the growing independence it has instilled in the consumer, the utility of the brick and mortar office location continues to diminish. Increasing numbers of consumers have little use for, and even less interest in visiting, a traditional real estate office. As a natural and inevitable consequence, substantial and growing numbers of real estate professionals are exiting traditional brokerage models, providing further evidence of the decline of the brick and mortar office.

Consumers leverage eXp’s internet marketing and cloud technology to find, buy or sell homes without a brick and mortar office. And finally, millions of Americans understand the benefits of technology and decreasing reliance on the traditional office. Despite these trends most traditional brokerages continue to allocate significant resources to physical locations.

As a cloud-based real estate brokerage eXp Realty has embraced and adopted a number of cloud-based technologies in order to grow an international brokerage without the burden of physical bricks and mortar and/or redundant staffing costs.

The Company has been engaged in the marketing and sale of residential real estate with the goal of being the first truly agent-owned, cloud-based, full service, global real estate brokerage company delivering around-the-clock access to collaborative tools and professional development for managing real estate brokers and agents. The business model was created in order to increase brokers’ and agents’ listings and sales and reduce their overhead and capital requirements.

Source: The Company, OxBridge Research, Daily Stock Deal, OTC King, OTC Stock Wire

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks. If you want to learn more or get your company featured on Daily Stock Deal, please contact the Editor. editor [@] DailyStockDeals.com

OMAG, Omagine selects a local bank, Phase 1 to start soon

E-mail

Written by Administrator

Omani bank appointed Omagine Phase 1 financial advisor

Located in Seeb, the Omagine project features seven pearl-shaped buildings, which will host hotels, offices, residences and entertainment venues, on one million square meters of land.

August 29, 2016

by Times News Service

Muscat: An Omani bank has been hired as a financial advisor and lender for phase one of the multi-billion dollar Omagine project, which is scheduled to begin in 2017.

The bank will deliver a term-sheet specifying debt financing and advisory services on or before September 4, to execute phase one of the project.

A term-sheet is a bullet point document outlining the material terms and conditions of a business agreement.

When asked whether Omagine will agree to the term sheet of the Omani bank, Omagine Chairman Frank J. Drohan said he will not be able to say until he sees it. “We are working on that process now,” he told the Times of Oman.

Located in Seeb, the project features seven pearl-shaped buildings, which will host hotels, offices, residences and entertainment venues, on one million square meters of land.

Phase one of the project is valued at approximately $220 million and will have one hotel, 250 residences and one pearl, said U.S.-based Omagine Inc. in its quarterly report filed with the U.S. Securities and Exchange Commission.

The company, however, did not disclose the name of the bank.

The project is expected to create more than 1,000 jobs for nationals when it is completed in seven years.

“During the July 19 to August 18, 2016 period, shareholders of Omagine LLC met several times, both separately and together, with the senior management of the Omani Bank and the Omani bank has agreed in principle to be the LLC’s financial adviser and to provide debt financing required for LLC to design, develop and construct phase one valued at approximately $220 million,” the company said in the report.

Source: Times of Oman

Daily Stock Deals, OxBridge Research, OTC King

OMAG, Omagine selects a local bank, Phase 1 to start soon

E-mail

Written by Administrator

Omani bank appointed Omagine Phase 1 financial advisor

August 29, 2016

by Times News Service

Located in Seeb, the Omagine project features seven pearl-shaped buildings, which will host hotels, offices, residences and entertainment venues, on one million square meters of land.